Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
Stopped Sponsor decision to prematurely stop the study. This decision was made without any safety concerns.
Conditions
Interventions
- BIOLOGICAL: Recombinant influenza vaccine (RIV4)
- BIOLOGICAL: Quadrivalent influenza vaccine (IIV4)
Sponsor
Sanofi Pasteur, a Sanofi Company